Dr. Ascierto on Triplet Therapy in BRAF+ Melanoma

Paolo A. Ascierto, MD
Published: Thursday, Aug 30, 2018



Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses investigational triplet therapies in patients with BRAF-positive melanoma.

Triplet regimens are of interest in patients with BRAF-positive melanoma, explains Ascierto. There are many ongoing studies that are examining triplet therapies, including a phase I trial with dabrafenib (Tafinlar) and trametinib (Mekinist) in combination with durvalumab (Imfinzi).

There are also ongoing phase II/III trials, says Ascierto, including the KEYNOTE-022 trial, which is looking at dabrafenib and trametinib in combination with pembrolizumab (Keytruda). These data will likely be presented at the 2018 ESMO Congress.

Additionally, the combination of vemurafenib (Zelboraf) and cobimetinib (Cotellic) with atezolizumab (Tecentriq) is being explored. These trials will seek to answer whether the addition of an anti–PD-1 therapy can induce a long-term benefit in these patients, says Ascierto.
SELECTED
LANGUAGE


Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses investigational triplet therapies in patients with BRAF-positive melanoma.

Triplet regimens are of interest in patients with BRAF-positive melanoma, explains Ascierto. There are many ongoing studies that are examining triplet therapies, including a phase I trial with dabrafenib (Tafinlar) and trametinib (Mekinist) in combination with durvalumab (Imfinzi).

There are also ongoing phase II/III trials, says Ascierto, including the KEYNOTE-022 trial, which is looking at dabrafenib and trametinib in combination with pembrolizumab (Keytruda). These data will likely be presented at the 2018 ESMO Congress.

Additionally, the combination of vemurafenib (Zelboraf) and cobimetinib (Cotellic) with atezolizumab (Tecentriq) is being explored. These trials will seek to answer whether the addition of an anti–PD-1 therapy can induce a long-term benefit in these patients, says Ascierto.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x